Celularity Inc (CELU)

Currency in USD
3.160
+0.040(+1.28%)
Closed·
After Hours
3.1600.000(0.00%)
·
CELU Scorecard
Full Analysis
Operates with a significant debt burden
CELU is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.9703.265
52 wk Range
1.0015.220
Key Statistics
Prev. Close
3.12
Open
3.11
Day's Range
2.97-3.265
52 wk Range
1.001-5.22
Volume
114.45K
Average Volume (3m)
245.13K
1-Year Change
3.14%
Book Value / Share
0.39
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CELU Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to drop this year

Celularity Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Sell

Celularity Inc Company Profile

Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn’s disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn’s) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.

Employees
123

Compare CELU to Peers and Sector

Metrics to compare
CELU
Peers
Sector
Relationship
P/E Ratio
−1.4x−0.4x−0.5x
PEG Ratio
−0.02−0.010.00
Price/Book
9.1x3.0x2.6x
Price / LTM Sales
1.5x10.0x3.3x
Upside (Analyst Target)
-292.6%45.1%
Fair Value Upside
Unlock23.9%7.4%Unlock

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.60 / -0.15
Revenue / Forecast
18.13M / --
EPS Revisions
Last 90 days

CELU Income Statement

People Also Watch

49.46
DIOD
+1.12%
7.365
TRON
-2.71%
1.00
KLTO
+8.54%
4.270
ATAI
+2.40%

FAQ

What Stock Exchange Does Celularity Trade On?

Celularity is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Celularity?

The stock symbol for Celularity is "CELU."

What Is the Celularity Market Cap?

As of today, Celularity market cap is 77.28M.

What Is Celularity's Earnings Per Share (TTM)?

The Celularity EPS (TTM) is -2.64.

From a Technical Analysis Perspective, Is CELU a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Celularity Stock Split?

Celularity has split 1 times.

How Many Employees Does Celularity Have?

Celularity has 123 employees.

What is the current trading status of Celularity (CELU)?

As of 04 Aug 2025, Celularity (CELU) is trading at a price of 3.16, with a previous close of 3.12. The stock has fluctuated within a day range of 2.97 to 3.27, while its 52-week range spans from 1.00 to 5.22.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.